Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 2 - Studien 11 bis 20 von insgesamt 31
- Rekrutierung läuftA Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination withDaratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib asInduction Therapy and Teclistamab in Combination with Daratumumab andLenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma
- Rekrutierung läuftPhase II Trial for the Treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and BlinatumomabMolekulare Marker
- Rekrutierung läuftIntravenöse Eisencarboxymaltose versus orale Eisensubstitution bei Patienten mit metastasiertem kolorektalen Karzinom (CRC) und Eisenmangelanämie: eine randomisierte, multizentrische Therapieoptimierungsstudie
- Rekrutierung läuftA RANDOMIZED, OPEN-LABEL, MULTICENTER, GLOBAL, PHASE 2 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF EPCORITAMAB (GEN3013; DUOBODY®-CD3×CD20) AS MONOTHERAPY OR IN COMBINATION WITH LENALIDOMIDE AS FIRST-LINE THERAPY FOR ANTHRACYCLINE-INELIGIBLE SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMAMolekulare Marker
- Rekrutierung läuftInternational Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Rekrutierung läuftLong-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified CellsMolekulare Marker
- Rekrutierung läuftA Phase 2 Multicenter Study Evaluating the efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA 2)Molekulare Marker
- Rekrutierung läuftSequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab
for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) - Rekrutierung läuftModified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - The randomized phase 2 MOONLIGHT trial.
- Rekrutierung läuftAn Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovirin Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas(NAVAL-1)Molekulare Marker